Today, companies including Religare Enterprises, Gland Pharma, Fortis Malar Hospitals, Aditya Birla Capital, Alembic Pharma, ...

The stocks of the companies announcing Q3 results will be kept under active watch. Notably, markets have been seeing a ...

In an exchange filing last month, the company had informed that a meeting of its Board of Directors is scheduled for this ...

A significant chunk of revenue for most Indian generic drugmaker comes from the U.S. and fierce competition in the North ...

Drug firm Divi's Laboratories on Monday said its profit after tax (PAT) increased 65 per cent to Rs 589 crore for the ...

Alembic Pharmaceuticals reported a 23.29% decline in Q3 FY25 net profit at ₹138.42 crore, despite a 3.81% revenue increase to ...

In the corresponding quarter of the previous fiscal, Alembic Pharmaceuticals posted a net profit of ₹180.4 crore. The company ...

Aditya Birla Capital recorded revenue from operations at Rs 9381.35 crore, up 9.28 per cent as against Rs 8584.50 crore ...

Divi's Labs also said in its exchange filing that it has commenced commercial operations from a part of the Phase 1 of the ...